Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Beta-Blockers in the Treatment of Hypertension.

Advances in experimental medicine and biology·2016
Same author

Hypertensive subjects with type-2 diabetes, the sympathetic nervous system, and treatment implications.

International journal of cardiology·2014
Same author

Evolving strategies for optimal care management and plan benefit designs.

The American journal of managed care·2013
Same author

Don't beta blockers still have a role in hypertension?

BMJ (Clinical research ed.)·2011
Same author

Achieving cholesterol targets: how well are we doing?

The Journal of the American Osteopathic Association·2011
Same author

Beta blockers in hypertension.

Lancet (London, England)·2010
Same journal

Letter to the Editor on "Clinical profile and optical coherence tomography based morphological characteristics of coronary in-stent restenosis: A cross-sectional study".

Indian heart journal·2026
Same journal

Evolving spectrum and outcomes of infective endocarditis in North India: A comparative analysis between people who inject drugs and those who do not.

Indian heart journal·2026
Same journal

Medical management of hypertrophic cardiomyopathy.

Indian heart journal·2026
Same journal

Response to the Letter to the Editor, "Reappraising the role of CMRI in HFpEF: A tiny step in the black and white world of HFpEF".

Indian heart journal·2026
Same journal

Indian society of electrocardiology position statement on improving CPR awareness in the Indian public.

Indian heart journal·2026
Same journal

Intracoronary thrombus in ST-segment elevation myocardial infarction: Practical management strategies for the interventional cardiologist.

Indian heart journal·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Beta-blockers and heart failure.

John M Cruickshank1

  • 1Independent Cardiovascular Consultant, Long Melford, Great Britain. johndtl@aol.com

Indian Heart Journal
|December 25, 2010
PubMed
Summary
This summary is machine-generated.

Beta-blockers (BB) are crucial for treating systolic heart failure (HF), reducing deaths by 34-5%. Specific BBs like bisoprolol, metoprolol, and carvedilol offer optimal efficacy, with careful selection vital for managing HF and hypertension.

Related Experiment Videos

Last Updated: Jun 5, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) poses a growing health burden due to increased longevity.
  • Hypertension and coronary artery disease (CAD) are primary causes of HF, with distinct mechanisms in systolic and diastolic HF.
  • Beta-blockers (BBs) are foundational in systolic HF treatment, alongside ACE-inhibitors.

Purpose of the Study:

  • To evaluate the efficacy of various beta-blockers (BBs) in treating heart failure (HF).
  • To compare the effectiveness of different BBs and their impact on mortality and adverse events.
  • To explore the role of BBs in preventing HF and managing hypertension-related cardiac conditions.

Main Methods:

  • Review of clinical trial data on beta-blocker efficacy in systolic and diastolic heart failure.
  • Analysis of BBs' mechanisms of action, including beta-1 and beta-2 blockade.
  • Assessment of BBs' impact on mortality, sudden death, and adverse reactions in HF patients.

Main Results:

  • BBs (bisoprolol, metoprolol, carvedilol) significantly reduce all-cause mortality in systolic HF by 34-5%.
  • First-line bisoprolol demonstrated non-inferiority to enalapril in reducing overall death and superiority in reducing sudden death.
  • BBs are effective in preventing HF post-myocardial infarction and in managing hypertension, including reversing left ventricular hypertrophy (LVH).

Conclusions:

  • Specific BBs like bisoprolol, metoprolol succinate, and carvedilol are recommended for optimal efficacy in HF treatment.
  • Intrinsic sympathomimetic activity (ISA) in BBs diminishes their effectiveness in systolic HF.
  • Careful BB selection is crucial, considering potential adverse effects related to beta-2 and alpha-blockade, and lipophilicity.